European Commission Approves Frontline Fulvestrant for ER+ Breast Cancer

July 27, 2017 – The European Commission (EC) has approved the use of fulvestrant to treat estrogen receptor (ER)-positive, locally-advanced or metastatic breast cancer in postmenopausal women not previously treated with endocrine therapy. The EC based its decision on results from the phase III FALCON trial, which showed that fulvestrant extended median progression-free survival (PFS) by 2.8 months compared with the aromatase inhibitor anastrozole … (leggi tutto)